L-Arginine for the Treatment of Centrally Obese Subjects: A Pilot Study.
Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrat...
| Publicado en: | Journal of Dietary Supplements Vol. 11; no. 1; pp. 40 - 53 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Mar2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104033243&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104033243 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19390211 2Y62 jtl: Journal of Dietary Supplements issn: 19390211 maglogo: N pubinfo: dt: Mar2014 vid: 11 iid: 1 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 104033243 94628117 10.3109/19390211.2013.859216 NLM24409974 104033243 ppf: 40 ppct: 13 formats: fmt: @attributes: type: P tig: atl: L-Arginine for the Treatment of Centrally Obese Subjects: A Pilot Study. aug: au: Hurt, Ryan T. Ebbert, Jon O. Schroeder, Darrell R. Croghan, Ivana T. Bauer, Brent A. McClave, Stephen A. Miles, John M. McClain, Craig J. affil: Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA sug: subj: Arginine Therapeutic Use Obesity Drug Therapy Weight Loss Human Adipose Tissue Waist Circumference Cardiovascular Risk Factors Prevention and Control Body Mass Index Waist-Hip Ratio Arginine Administration and Dosage Female Life Style Changes Arginine Blood Descriptive Statistics Dietary Supplementation Prospective Studies Questionnaires Blood Analysis Center for Epidemiological Studies Depression Scale Psychological Tests Depression Paired T-Tests Amino Acids Blood Comparative Studies Confidence Intervals Marital Status Educational Status Pilot Studies Female ab: Background: Visceral adiposity has been linked to higher rates of cardiometabolic risk than other types of adiposity. Waist circumference (WC) is the best anthropomorphic surrogate of visceral adiposity. Reductions in central adiposity may decrease cardiovascular risk. Animal studies have demonstrated that L-arginine reduces visceral adiposity and fat mass. The primary aim of our study was to assess the efficacy of L-arginine for reducing central adiposity in nondiabetic obese subjects. Secondary aims were to assess the efficacy of L-arginine for decreasing body mass index (BMI), waist-to-hip ratio (WHR), and weight. Materials and Methods: Female subjects ( n = 20) were included if they: were ≥ 18 years and ≤ 40 years of age, had a BMI of ≥ 30 and ≤ 40 kg/m2, had a WC ≥ 89 cm. Subjects received 3 g of L-arginine three times a day for 12 weeks and were counseled on lifestyle modification. Results: Overall, L-arginine was well tolerated with no clinically significant adverse events. Serum L-arginine levels were significantly increased from baseline at both 6 and 12 weeks ( p < .05). WC (mean ± SD) decreased from 115.6 ± 12.7 cm at baseline to 109.2 ± 11.7 cm at 12 weeks ( p = .0004). Weight (mean ± SD) decreased from 98.6 ± 19.7 kg at baseline to 95.7 ± 18.6 kg at 12 weeks ( p = .015). Significant reductions from baseline were also observed in BMI and WHR. Conclusions: L-Arginine may be effective at reducing central adiposity in obese patients. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|